

# Marina P Cristelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3742482/publications.pdf>

Version: 2024-02-01

63  
papers

635  
citations

687363

13  
h-index

713466

21  
g-index

63  
all docs

63  
docs citations

63  
times ranked

943  
citing authors

#	ARTICLE	IF	CITATIONS
1	Migratory pattern of the coronavirus disease 2019 and high fatality rates among kidney transplant recipients: report from the Brazilian Multicenter Cohort Study. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2022, 44, 428-433.	0.9	5
2	Development and validation of a simple web-based tool for early prediction of COVID-19-associated death in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 610-625.	4.7	16
3	Efficacy of Convalescent Plasma to Treat Mild to Moderate COVID-19 in Kidney Transplant Patients: A Propensity Score Matching Analysis. <i>Transplantation</i> , 2022, 106, e92-e94.	1.0	21
4	A Stentless Modified Lich-Gregoir Technique for Safe Early Bladder Catheter Removal in Living and Deceased Kidney Transplants. <i>Urology</i> , 2022, , .	1.0	0
5	<i>Aspergillus fumigatus</i> as an agent of secondary cutaneous aspergillosis in a renal transplant recipient: a case report. <i>International Journal of Dermatology</i> , 2022, , .	1.0	2
6	Predictive ability of severity scores and outcomes for mortality in kidney transplant recipients with coronavirus disease 2019 admitted to the intensive care unit: results from a Brazilian single-center cohort study. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2022, 44, 383-394.	0.9	2
7	The Higher COVID-19 Fatality Rate Among Kidney Transplant Recipients Calls for Further Action. <i>Transplantation</i> , 2022, 106, 908-910.	1.0	15
8	Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results. <i>Transplantation</i> , 2022, 106, 853-861.	1.0	13
9	Oral findings in kidney transplant children and adolescents. <i>International Journal of Paediatric Dentistry</i> , 2022, , .	1.8	1
10	Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 816-817.	2.9	2
11	COVID-19 Among Kidney Transplant Recipients: A Look Into Latin America. <i>Transplantation</i> , 2022, 106, e185-e186.	1.0	4
12	The Mycophenolate-based Immunosuppressive Regimen Is Associated With Increased Mortality in Kidney Transplant Patients With COVID-19. <i>Transplantation</i> , 2022, 106, e441-e451.	1.0	4
13	Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti- $\epsilon$ thymocyte globulin without CMV prophylaxis â€“ a cohort single- $\epsilon$ center study. <i>Transplant International</i> , 2021, 34, 339-352.	1.6	6
14	Kidney Transplantation in Patients With SARS-CoV-2 Infection: A Case Series Report. <i>Transplantation</i> , 2021, 105, e1-e3.	1.0	8
15	Strategies to keep kidney transplant alive amid the SARS-CoV-2 pandemic. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2021, 67, 63-66.	0.7	4
16	Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	1.0	3
17	The Full Spectrum of COVID-19 Development and Recovery Among Kidney Transplant Recipients. <i>Transplantation</i> , 2021, 105, 1433-1444.	1.0	30
18	Kidney transplantation in the time of COVID-19: Dilemmas, experiences, and perspectives. <i>Transplant Infectious Disease</i> , 2021, 23, e13600.	1.7	7

#	ARTICLE	IF	CITATIONS
19	The influence of the antithymocyte globulin dose on clinical outcomes of patients undergoing kidney retransplantation. PLoS ONE, 2021, 16, e0251384.	2.5	4
20	<sc>HLA</sc> homozygosity is associated with susceptibility to <sc>COVID</sc>. Hla, 2021, 98, 122-131.	0.6	14
21	High mortality among kidney transplant recipients diagnosed with coronavirus disease 2019: Results from the Brazilian multicenter cohort study. PLoS ONE, 2021, 16, e0254822.	2.5	51
22	Clinical impact, reactogenicity, and immunogenicity after the first CoronaVac dose in dialysis patients: a phase IV prospective study. CKJ: Clinical Kidney Journal, 2021, 14, 2612-2615.	2.9	3
23	Lower seroprevalence for SARS-CoV-2-specific antibodies among kidney transplant recipients compared to the general population in the city of Sao Paulo, Brazil. Transplant Infectious Disease, 2021, 23, e13706.	1.7	5
24	Challenges of Multidrug-resistant New Delhi Metallo-beta-Lactamase (NDM-1)-producing Enterobacteriaceae in Kidney Transplant Patients. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, , .	0.9	2
25	Comparison of 30-day case-fatality rate between dialysis and transplant Covid-19 patients: a propensity score matched cohort study. Journal of Nephrology, 2021, 35, 131.	2.0	6
26	Global Perspective on Kidney Transplantation: Brazil. Kidney360, 2021, 2, 2016-2018.	2.1	2
27	Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes. PLoS ONE, 2020, 15, e0227445.	2.5	12
28	Oral manifestations of allograft recipients immediately before and after kidney transplantation. Acta Odontologica Scandinavica, 2020, 78, 217-222.	1.6	5
29	The Influence of Antithymocyte Globulin Dose on the Incidence of CMV Infection in High-risk Kidney Transplant Recipients Without Pharmacological Prophylaxis. Transplantation, 2020, 104, 2139-2147.	1.0	12
30	Herpesviruses oral shedding and viremia in renal transplant recipients: A longitudinal study. Transplant Infectious Disease, 2020, 22, e13330.	1.7	1
31	Title is missing!. , 2020, 15, e0227445.		0
32	Title is missing!. , 2020, 15, e0227445.		0
33	Title is missing!. , 2020, 15, e0227445.		0
34	Title is missing!. , 2020, 15, e0227445.		0
35	Prospective randomized study comparing everolimus and mycophenolate sodium in<i>de novo</i> kidney transplant recipients from expanded criteria deceased donor. Transplant International, 2019, 32, 1127-1143.	1.6	15
36	Chikungunya in a kidney transplant recipient: a case report. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2019, 41, 575-579.	0.9	5

#	ARTICLE	IF	CITATIONS
37	Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy. <i>Transplant Infectious Disease</i> , 2019, 21, e13106.	1.7	10
38	Clinical features and outcomes of kidney transplant recipients with focal segmental glomerulosclerosis recurrence. <i>Nephrology</i> , 2019, 24, 1179-1188.	1.6	4
39	Early hospital readmission after kidney transplantation under a public health care system. <i>Clinical Transplantation</i> , 2019, 33, e13467.	1.6	13
40	Influence of epidemiology, immunosuppressive regimens, clinical presentation, and treatment on kidney transplant outcomes of patients diagnosed with tuberculosis: A retrospective cohort analysis. <i>American Journal of Transplantation</i> , 2019, 19, 1421-1431.	4.7	22
41	The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive recipient negative (D+/R <sup>-</sup> ) kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12907.	1.7	10
42	Sexual acquisition of HIV infection after solid organ transplantation: Late presentation and potentially fatal complications. <i>Transplant Infectious Disease</i> , 2018, 20, e12894.	1.7	5
43	The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis. <i>Transplant Infectious Disease</i> , 2018, 20, e12919.	1.7	7
44	Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy. <i>Brazilian Journal of Infectious Diseases</i> , 2018, 22, 193-201.	0.6	13
45	The influence of clinical, environmental, and socioeconomic factors on five-year patient survival after kidney transplantation. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2018, 40, 151-161.	0.9	11
46	Prospective Randomized Trial Investigating the Influence of Pharmaceutical Care on the Intra-Individual Variability of Tacrolimus Concentrations Early After Kidney Transplant: Erratum. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 579-579.	2.0	24
47	Infectious complications as the leading cause of death after kidney transplantation: analysis of more than 10,000 transplants from a single center. <i>Journal of Nephrology</i> , 2017, 30, 601-606.	2.0	35
48	Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3-year retrospective cohort study. <i>Transplant Infectious Disease</i> , 2017, 19, e12724.	1.7	3
49	Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus. <i>American Journal of Nephrology</i> , 2017, 45, 497-508.	3.1	15
50	Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. <i>Transplantation</i> , 2017, 101, 844-850.	1.0	30
51	Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months). <i>Value in Health Regional Issues</i> , 2017, 14, 108-115.	1.2	6
52	The current burden of cytomegalovirus infection in kidney transplant recipients receiving no pharmacological prophylaxis. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2017, 39, 413-423.	0.9	12
53	Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 22-31.	2.0	17
54	Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation. <i>Brazilian Journal of Infectious Diseases</i> , 2016, 20, 576-584.	0.6	14

#	ARTICLE	IF	CITATIONS
55	Renal transplantation in human immunodeficiency virus-infected recipients: a case-control study from the Brazilian experience. <i>Transplant Infectious Disease</i> , 2016, 18, 730-740.	1.7	6
56	The Effect of Corticosteroid Withdrawal on Glucose Metabolism and Anti-GAD Antibodies in Simultaneous Pancreas-Kidney Transplant Patients. <i>Progress in Transplantation</i> , 2016, 26, 249-254.	0.7	1
57	De novo everolimus for recipients of kidney transplants from HLA identical donors. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2016, 38, 225-33.	0.9	2
58	Prognosis of Patients with Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (PTLD-CNS) Treated with Immunossuppression Reduction, Intrathecal Chemotherapy and Whole-Brain Radiotherapy: An Analysis of 23 Patients in a Brazilian Cohort. <i>Blood</i> , 2015, 126, 3913-3913.	1.4	3
59	Prolonged Delayed Graft Function Is Associated with Inferior Patient and Kidney Allograft Survivals. <i>PLoS ONE</i> , 2015, 10, e0144188.	2.5	61
60	Clinical Outcome of 96 Post-Transplant Lymphoproliferative Disease Patients in a Renal Transplant Cohort. <i>Blood</i> , 2015, 126, 5054-5054.	1.4	0
61	Clinicopathological Characteristics and Effect of Late Acute Rejection on Renal Transplant Outcomes. <i>Transplantation</i> , 2014, 98, 885-892.	1.0	14
62	Expanding the use of expanded criteria donors in kidney transplantation. <i>International Urology and Nephrology</i> , 2014, 46, 1663-1671.	1.4	7
63	Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids. <i>Transplant Infectious Disease</i> , 2013, 15, 369-378.	1.7	10